Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IDXX, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
IDXX holds $197.5M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IDXX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vanguard Capital Management | Institution (13G, 5%+) | 5,976,472 | 7.59% | 2026-03-31 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 3,974,472 | 5.04% | 2026-09-30 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director · +1,099 options |
Insider | 83,803 | 0.11% | 2026-11-04 |
| Nimrata Hunt Executive Vice President · +4,787 options |
Insider | 18,301 | 0.02% | 2026-03-03 |
| Michael G Erickson Executive Vice President · +13,829 options |
Insider | 15,092 | 0.02% | 2026-02-17 |
| George Fennell Executive Vice President · +3,546 options |
Insider | 12,182 | 0.02% | 2026-11-10 |
| Lawrence D Kingsley Director · +243 options |
Insider | 9,568 | 0.01% | 2026-09-04 |
| Sophie V. Vandebroek Director · +759 options |
Insider | 9,078 | 0.01% | 2026-05-07 |
| Sharon E. Underberg EVP, GC & Corporate Secretary · +4,695 options |
Insider | 7,169 | 0.01% | 2026-11-04 |
| Michael Lane Executive Vice President · +6,125 options |
Insider | 4,668 | 0.01% | 2026-11-04 |
| Andrew Emerson EVP, CFO and Treasurer · +5,938 options |
Insider | 4,421 | 0.01% | 2026-08-20 |
| Michael Schreck Executive Vice President · +4,787 options |
Insider | 3,089 | 0.00% | 2026-02-12 |
Share count 78,786,265 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IDXX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →